A Molecularly Driven Pilot Study of Preoperative Ganetespib in Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

A Molecularly Driven Pilot Study of Preoperative Ganetespib in Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Ganetespib (Primary)
  • Indications Head and neck cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 22 Jul 2016 Status changed from active, no longer recruiting to discontinued due to funding.
    • 03 Mar 2016 Study phase changed from phase 0 to phase I according to ClinicalTrials.gov record.
    • 03 Mar 2016 Planned End Date changed from 1 Dec 2017 to 1 Mar 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top